HAMILTON, ONT. — 05/01/16 — Fusion Pharmaceuticals, Inc. (“Fusion”), a life sciences company focused on developing novel drugs for the targeted delivery of high-energy alpha-emitting radioactive isotopes to treat solid cancers, announced today that it will be featured as a presenting company at The Biotech Showcase™ 2016 Conference taking place from January 11-13, 2016. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California.
Chief Business Officer, Frank Gleeson, is scheduled to present on Monday, January 11, 2016 at 11:15 AM PST in Room Hearst. Frank Gleeson, Dr. Valliant, Founder and Chief Executive Officer and Dr. Eric Burak, Chief Scientific Officer, will be available to participate in meetings with the investment community during the conference.
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a clinical stage company focused on developing novel radiotherapeutics for the treatment of cancer. Fusion is a spin-out from the Centre for Probe Development and Commercialization (CPDC) at McMaster University, Hamilton. Please visit the website at fusionpharma.com.
About The Biotech Showcase 2016 Conference
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.